INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $50,783,270 | +12.1% | 974,914 | +36.3% | 0.02% | +15.4% |
| Q2 2023 | $45,304,827 | +19.6% | 715,490 | +2.3% | 0.01% | +8.3% |
| Q1 2023 | $37,871,914 | +2.7% | 699,389 | +0.4% | 0.01% | 0.0% |
| Q4 2022 | $36,874,868 | +16.5% | 696,804 | +2.4% | 0.01% | +9.1% |
| Q3 2022 | $31,662,000 | -11.4% | 680,459 | +8.7% | 0.01% | -8.3% |
| Q2 2022 | $35,719,000 | -4.0% | 625,764 | +3.0% | 0.01% | +9.1% |
| Q1 2022 | $37,188,000 | +37.0% | 607,737 | +17.2% | 0.01% | +37.5% |
| Q4 2021 | $27,138,000 | +42.9% | 518,477 | +1.8% | 0.01% | +33.3% |
| Q3 2021 | $18,995,000 | -5.2% | 509,500 | +3.8% | 0.01% | -14.3% |
| Q2 2021 | $20,044,000 | +24.3% | 491,013 | +3.3% | 0.01% | +16.7% |
| Q1 2021 | $16,122,000 | +10.7% | 475,134 | +3.7% | 0.01% | 0.0% |
| Q4 2020 | $14,564,000 | +28.0% | 457,962 | +3.3% | 0.01% | +20.0% |
| Q3 2020 | $11,377,000 | +21.3% | 443,373 | +21.3% | 0.01% | 0.0% |
| Q2 2020 | $9,380,000 | +79.9% | 365,376 | +7.7% | 0.01% | +66.7% |
| Q1 2020 | $5,215,000 | -45.5% | 339,286 | +21.6% | 0.00% | -40.0% |
| Q4 2019 | $9,577,000 | +367.9% | 279,124 | +1.9% | 0.01% | +400.0% |
| Q3 2019 | $2,047,000 | -41.9% | 273,955 | +1.0% | 0.00% | -50.0% |
| Q2 2019 | $3,522,000 | +8.1% | 271,280 | +1.5% | 0.00% | 0.0% |
| Q1 2019 | $3,257,000 | +12.1% | 267,340 | +4.8% | 0.00% | 0.0% |
| Q4 2018 | $2,906,000 | -48.2% | 255,051 | -1.3% | 0.00% | -50.0% |
| Q3 2018 | $5,606,000 | +30.5% | 258,295 | +6.2% | 0.00% | +33.3% |
| Q2 2018 | $4,297,000 | -10.4% | 243,177 | +6.8% | 0.00% | -25.0% |
| Q1 2018 | $4,796,000 | +49.5% | 227,798 | +2.9% | 0.00% | +33.3% |
| Q4 2017 | $3,207,000 | +52.6% | 221,441 | +66.3% | 0.00% | +50.0% |
| Q3 2017 | $2,102,000 | +26.0% | 133,183 | -0.8% | 0.00% | 0.0% |
| Q2 2017 | $1,668,000 | -25.6% | 134,285 | -2.7% | 0.00% | 0.0% |
| Q1 2017 | $2,243,000 | +13.7% | 137,975 | +5.6% | 0.00% | 0.0% |
| Q4 2016 | $1,972,000 | +4.4% | 130,640 | +5.4% | 0.00% | 0.0% |
| Q3 2016 | $1,889,000 | -56.1% | 123,931 | +11.7% | 0.00% | -60.0% |
| Q2 2016 | $4,307,000 | +59.4% | 110,947 | +14.2% | 0.01% | +25.0% |
| Q1 2016 | $2,702,000 | -47.2% | 97,165 | +2.1% | 0.00% | -42.9% |
| Q4 2015 | $5,117,000 | +97.0% | 95,128 | +46.7% | 0.01% | +75.0% |
| Q3 2015 | $2,597,000 | +11.1% | 64,849 | -11.3% | 0.00% | +33.3% |
| Q2 2015 | $2,337,000 | +51.7% | 73,123 | +13.3% | 0.00% | +50.0% |
| Q1 2015 | $1,541,000 | +43.8% | 64,516 | +6.3% | 0.00% | 0.0% |
| Q4 2014 | $1,072,000 | +73.7% | 60,699 | +35.1% | 0.00% | +100.0% |
| Q3 2014 | $617,000 | -16.3% | 44,931 | +2.8% | 0.00% | 0.0% |
| Q2 2014 | $737,000 | +113.0% | 43,712 | +130.1% | 0.00% | 0.0% |
| Q1 2014 | $346,000 | – | 18,996 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |